Brief: Northstrive Biosciences, Subsidiary of PMGC Holdings, Reports Positive Updates for Obesity Drug Candidates Targeting Fat Loss and Muscle Preservation used in Combination with GLP-1
04/02/2025 14:27
Feb 4 (Reuters) - PMGC Holdings Inc ELAB.O :
* PMGC UNIT, NORTHSTRIVE, SAYS PREPARING FOR FDA
INVESTIGATIONAL
NEW DRUG FILING FOR EL-22
* NORTHSTRIVE - ANTICIPATES TYPE B PRE-IND MEETING WITH FDA
IN Q2
2025
Source text: ID:nGNX8gZXxS
Further company coverage: ELAB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on PMGC Holdings
See all newsBrief: PMGC Holdings Signs Non-Binding Letter Of Intent To Acquire Majority Stake In US-Based Precision Machining Manufacturing Company Serving Aerospace, Space, Defense, And Semiconductor Markets
Brief: PMGC Holdings Offers $7.8 Million In Common Stock To Streeterville Capital
NASDAQ RESUMED AT 12:33 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:28 PM
NASDAQ RESUMED AT 09:46 AM